Chidamide Sintilimab Bevacizumab Second-Line Neuroendocrine Carcinoma
Summary
ClinicalTrials.gov registered a new Phase 2 trial (NCT07518602) evaluating the combination of chidamide, sintilimab, and bevacizumab as second-line treatment for patients with advanced neuroendocrine carcinoma. The single-arm study will assess objective response rate and safety profile of the triple-drug regimen. No compliance obligations are created by this informational registration.
What changed
ClinicalTrials.gov published a new trial registration for a Phase 2 single-arm study evaluating the efficacy and safety of chidamide, sintilimab, and bevacizumab as second-line treatment for advanced neuroendocrine carcinoma. The study will enroll eligible patients and measure objective response rate as the primary endpoint.
This is an informational clinical trial registration and does not create any compliance obligations for sponsors, manufacturers, or healthcare providers. Pharmaceutical companies developing similar targeted therapies may find this study relevant for competitive intelligence or potential partnership opportunities.
What to do next
- Monitor for trial results publication
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.